204 related articles for article (PubMed ID: 15601331)
1. Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: Report on a survey of radiotherapy centres and the proceedings of a consensus workshop.
Tai KH; Duchesne G; Turner S; Kneebone A; See A; Gogna K; Berry M
Australas Radiol; 2004 Dec; 48(4):502-8. PubMed ID: 15601331
[TBL] [Abstract][Full Text] [Related]
2. Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer.
Skala M; Berry M; Duchesne G; Gogna K; Tai KH; Turner S; Kneebone A; Rolfo A; Haworth A
Australas Radiol; 2004 Dec; 48(4):493-501. PubMed ID: 15601330
[TBL] [Abstract][Full Text] [Related]
3. Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma.
Hayden AJ; Martin JM; Kneebone AB; Lehman M; Wiltshire KL; Skala M; Christie D; Vial P; McDowall R; Tai KH;
J Med Imaging Radiat Oncol; 2010 Dec; 54(6):513-25. PubMed ID: 21199428
[TBL] [Abstract][Full Text] [Related]
4. RE: Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: report on a survey of radiotherapy centres by K-H Tai et al.
Izard MA
Australas Radiol; 2005 Jun; 49(3):256-7. PubMed ID: 15932473
[No Abstract] [Full Text] [Related]
5. Australia-wide comparison of intensity modulated radiation therapy prostate plans.
Skala M; Holloway L; Bailey M; Kneebone A
Australas Radiol; 2005 Jun; 49(3):222-9. PubMed ID: 15932465
[TBL] [Abstract][Full Text] [Related]
6. Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer.
Yuen J; Rodrigues G; Trenka K; Coad T; Yartsev S; D'Souza D; Lock M; Bauman G
Radiat Oncol; 2008 Jan; 3():1. PubMed ID: 18179695
[TBL] [Abstract][Full Text] [Related]
7. [Constraints and dosage for prostate cancer patients treated with conformal radiotherapy and intensity modulated radiation therapy].
Chauvet I; Gaboriaud G; Pontvert D; Zefkili S; Giraud P; Rosenwald JC; Cosset JM
Cancer Radiother; 2004 Dec; 8(6):337-51. PubMed ID: 15619378
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
9. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
10. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
[TBL] [Abstract][Full Text] [Related]
11. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.
Mock U; Bogner J; Georg D; Auberger T; Pötter R
Strahlenther Onkol; 2005 Jul; 181(7):448-55. PubMed ID: 15995838
[TBL] [Abstract][Full Text] [Related]
12. Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.
Haworth A; Kearvell R; Greer PB; Hooton B; Denham JW; Lamb D; Duchesne G; Murray J; Joseph D
Radiother Oncol; 2009 Mar; 90(3):299-306. PubMed ID: 19017549
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
14. Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder.
Hindson BR; Turner SL; Millar JL; Foroudi F; Gogna NK; Skala M; Kneebone A; Christie DR; Lehman M; Wiltshire KL; Tai KH;
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):18-30. PubMed ID: 22339742
[TBL] [Abstract][Full Text] [Related]
15. Technological advances in radiotherapy for the treatment of localised prostate cancer.
Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
[TBL] [Abstract][Full Text] [Related]
16. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
Matzinger O; Poortmans P; Giraud JY; Maingon P; Budiharto T; van den Bergh AC; Davis JB; Musat E; Ataman F; Huyskens DP; Gulyban A; Bolla M;
Radiother Oncol; 2009 Mar; 90(3):285-90. PubMed ID: 19038468
[TBL] [Abstract][Full Text] [Related]
17. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group.
Sidhom MA; Kneebone AB; Lehman M; Wiltshire KL; Millar JL; Mukherjee RK; Shakespeare TP; Tai KH
Radiother Oncol; 2008 Jul; 88(1):10-9. PubMed ID: 18514340
[TBL] [Abstract][Full Text] [Related]
18. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
19. IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization.
Vlachaki MT; Teslow TN; Amosson C; Uy NW; Ahmad S
Med Dosim; 2005; 30(2):69-75. PubMed ID: 15922172
[TBL] [Abstract][Full Text] [Related]
20. Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run.
Kouloulias VE; Giraud JY; Davis BJ; Dusserre A; Zurlo A; Bolla M
Radiother Oncol; 2004 Oct; 73(1):11-20. PubMed ID: 15465141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
